Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effects of Denosumab on the Pharmacokinetics of Etanercept

This study has been terminated.
(The study was stopped because only 38% of subjects had been enrolled after 5 years and multiple protocol amendments aimed at improving enrollment.)
Information provided by (Responsible Party):
Amgen Identifier:
First received: January 13, 2011
Last updated: March 8, 2016
Last verified: March 2016
This is a multi-center, open-label, single sequence, denosumab single-dose study in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis (RA) being treated with etanercept.

Condition Intervention Phase
Rheumatoid Arthritis
Drug: Etanercept
Drug: Denosumab
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Area under the serum concentration-time curve (AUC) from 0 to 168 hours for etanercept. [ Time Frame: A period of 21 days following denosumab administration. ] [ Designated as safety issue: No ]
  • Maximum observed serum concentration (Cmax) for etanercept. [ Time Frame: A period of 21 days following denosumab administration. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to maximum serum concentration (tmax) for etanercept. [ Time Frame: A period of 21 days following denosumab administration. ] [ Designated as safety issue: No ]
  • Serum denosumab concentration. [ Time Frame: At 14 and 21 days following denosumab administration. ] [ Designated as safety issue: No ]
  • Serum C-telopeptide (sCTx) concentrations. [ Time Frame: A period of 168 days following denosumab administration. ] [ Designated as safety issue: No ]

Enrollment: 19
Study Start Date: March 2011
Study Completion Date: January 2016
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Denosumab
All 44 subjects will receive denosumab.
Drug: Etanercept
All 44 subjects will continue to receive a 50-mg dose of etanercept once weekly.
All 44 subjects will receive etanercept.
Drug: Denosumab
All 44 subjects will receive a single 60-mg dose of denosumab.


Ages Eligible for Study:   45 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal women (postmenopausal is defined as no vaginal bleeding or spotting for at least 12 months)
  • Low bone mineral density (BMD) as determined by screening BMD T-scores of the lumbar spine (L1 to L4), or total evaluable vertebrae (if fewer than L1 to L4), or total hip ≤ -1.0
  • Receiving a 50-mg dose of etanercept once weekly ≥ 6 months prior to screening and expected to continue etanercept treatment at this dose and frequency through EOS
  • If currently taking methotrexate (MTX), receiving a stable dose (7.5 to 20 mg/week) of MTX ≥ 8 weeks prior to screening
  • Willing and able to take ≥ 1,000 mg elemental calcium and ≥ 400 IU vitamin D daily upon enrollment

Exclusion Criteria:

  • Type 1 diabetes; OR poorly controlled Type 2 diabetes (hemoglobin A1c (HbA1c) > 8.0% at screening; HbA1c ≤ 8.0% within 6 months of screening is acceptable if supporting laboratory documentation is available)
  • History of heart failure, coronary artery bypass graft, or cardiac arrhythmia; OR history of acute coronary syndrome
  • Comorbid autoimmune disease, demyelinating disease, or hematologic abnormalities
  • History of joint replacement in hand and/or wrist; OR history of fused joint in hand and/or wrist
  • Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw; OR active dental or jaw condition that requires oral surgery, or non-healed dental/oral surgery; OR planned invasive dental procedure(s) during the course of the study
  • Previous exposure to denosumab
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01294397

United States, Pennsylvania
Research Site
Duncansville, Pennsylvania, United States, 16635
United States, Texas
Research Site
Dallas, Texas, United States, 75231
Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT01294397     History of Changes
Other Study ID Numbers: 20101324 
Study First Received: January 13, 2011
Last Updated: March 8, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Amgen:
Phase 1
Bone Mineral Density

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Bone Diseases, Metabolic
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Bone Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors
Bone Density Conservation Agents processed this record on October 28, 2016